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Abstract
 
Chronic lymphocytic leukemia (CLL) arises from the clonal expansion of a CD5
 
 
 
 B lympho-
cyte that is thought not to undergo intraclonal diversification. Using V
 
H
 
DJ
 
H
 
 cDNA single
strand conformation polymorphism analyses, we detected intraclonal mobility variants in 11 of
18 CLL cases. cDNA sequence analyses indicated that these variants represented unique point-
mutations (1–35/patient). In nine cases, these mutations were unique to individual submem-
bers of the CLL clone, although in two cases they occurred in a large percentage of the clonal
submembers and genealogical trees could be identified. The diversification process responsible
for these changes led to single nucleotide changes that favored transitions over transversions,
but did not target A nucleotides and did not have the replacement/silent nucleotide change
characteristics of antigen-selected B cells. Intraclonal diversification did not correlate with the
original mutational load of an individual CLL case in that diversification was as frequent in
CLL cells with little or no somatic mutations as in those with considerable mutations. Finally,
CLL B cells that did not exhibit intraclonal diversification in vivo could be induced to mutate
their V
 
H
 
DJ
 
H
 
 genes in vitro after stimulation. These data indicate that a somatic mutation mech-
anism remains functional in CLL cells and could play a role in the evolution of the clone.
Key words: B lymphocyte • chronic lymphocytic leukemia • somatic hypermutation • Ig gene • 
V gene diversiﬁcation
 
Introduction
 
Chronic lymphocytic leukemia (CLL)
 
*
 
 is the most preva-
lent adult leukemia in Western countries, accounting for
 
 
 
30% of all leukemias (1). It is characterized by the clonal
expansion of a CD5
 
 
 
 B cell (2) that was in the past viewed
as having a poor propensity to undergo Ig V(D)J gene hy-
permutation (3–7). This view, however, changed when it
was documented that the leukemic cells from 
 
 
 
60% of
CLL patients express Ig V
 
H
 
 gene somatic point-mutations
(8–13). The frequency of these mutations relates to the V
 
H
 
family expressed, being higher in those cells expressing V
 
H
 
3
genes than in those expressing V
 
H
 
1 and V
 
H
 
4 (13). How-
ever, even those studies that described CLL cases with a
very high number of somatic mutations reported that these
mutations were shared by all the CLL B cells, strongly
suggesting that intraclonal diversification does not occur in
these leukemic B cells (14–17).
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Intraclonal Diversification in CLL B Cells
 
The lack of intraclonal diversification in CLL B cells was
considered consistent with the absence or scarcity of so-
matic mutations in human (2, 18) and murine (19–21) B1a
cells. This, however, was not supported by the findings that
human CD5
 
 
 
 B cells can undergo somatic hypermutation,
antigen selection, and possibly affinity maturation (22–25).
Rather, these findings supported the postgerminal center-
like features that have been recently suggested to be charac-
teristic of certain CLL cases such as V gene mutations (13),
CD38 expression (26), and in vivo isotype class switching
(6, 9, 11, 13, 27–29).
Prompted by these discrepancies and the recent ad-
vances in the understanding and induction of somatic hy-
permutation in human B cells (30–33), we decided to
determine whether CLL B cells continue to develop V
gene mutations after leukemic transformation and, there-
fore, intraclonally diversify. Using a highly sensitive and
ad hoc devised approach (32) based on single-strand
DNA conformational polymorphism (SSCP), we deter-
mined that intraclonal V
 
H
 
DJ
 
H
 
 gene diversification and
clonal evolution are common features of the in vivo nat-
ural history of many CLL B cells. In addition, using ap-
propriate stimuli, we induced somatic mutations in vitro
in those leukemic B cells that did not show evidence of
in vivo intraclonal diversification. These findings indicate
that a hypermutation machinery is functional and active
in certain CLL B cells and further point to the impor-
tance of a germinal center-like reaction in some of these
B lymphocytes.
 
Materials and Methods
 
CLL Patients and B Cells.
 
The 18 patients (12 males and six
females) in this study were diagnosed with typical B cell CLL
based on clinical criteria and laboratory features. All cases repre-
sented clonal expansions of small lymphocytes with high nuclear/
cytoplasmic ratios that coexpressed CD19, CD5, CD23, and
CD27 along with monotypic H and L chain surface membrane
Ig. The median age of the group at the time of analysis was 60 y
with a distribution of clinical Rai stages as follows: 10 patients in
stages O-II and eight patients in stages III-IV. PBMCs from these
patients were obtained from heparinized venous blood by frac-
tionation through Histopaque 1077
 
®
 
 (Sigma-Aldrich). B lym-
phocytes were enriched from PBMCs by depletion of T cells and
monocytes as described previously (31). All patients provided in-
formed consent before giving blood samples.
 
PCR Amplification of V(D)J Transcripts.
 
RNA was extracted
from 2 
 
 
 
 10
 
6
 
 B cells using the RNeasy™ Total RNA kit
(QIAGEN). mRNA was reverse transcribed using the Super-
Script™ Preamplification System for first strand cDNA synthesis
(Life Technologies, Inc.). V
 
H
 
DJ
 
H
 
-C
 
H
 
 cDNAs were amplified us-
ing sense primers specific for the sequences of the different V
 
H
 
families together with the antisense primers specific for the C
 
H
 
1-
 
 
 
sequence (13, 32) and the 
 
Pfu
 
 Turbo
 
®
 
 DNA polymerase (Strat-
agene). Each reaction consisted of 30 cycles (1 min denaturation
at 94
 
 
 
C, 1 min annealing at 58
 
 
 
C, 1 min extension at 72
 
 
 
C, and
10 min extension at 72
 
 
 
C). The PCR cDNA products were puri-
fied, ligated into pCR-Blunt II-TOPO vector (Zero Blunt™
TOPO™ Cloning kit; Invitrogen), and transfected in TOP10
One Shot™ competent cells (Invitrogen). Bacterial colonies were
 
screened by PCR and those positive for V
 
H
 
DJ
 
H
 
-C
 
H
 
 transcripts
were selected for SSCP analysis.
 
Detection of Mutated V
 
H
 
DJ
 
H
 
 Transcripts by SSCP.
 
Mutated
V
 
H
 
DJ
 
H
 
 transcripts were identified by SSCP analysis as described
previously (32). In brief, cDNAs were amplified with 
 
Taq
 
 DNA
polymerase (Life Technologies, Inc.) by PCR using the cloned
cDNA inserted into pCR-Blunt II-TOPO vector as template,
in the presence of 1 
 
 
 
Ci [
 
 
 
-
 
32
 
P] dCTP (3,000 Ci/mmol; NEN
Life Sciences). The internal V
 
H
 
 leader sense primer and J
 
H
 
 anti-
sense primer (31) were used for V
 
H
 
DJ
 
H
 
 analysis. Samples were
denatured and immediately loaded onto a 6% acrylamide gel
(20:1 acrylamide:bis) with 1 
 
 
 
 TBE containing 10% Glycerol.
Electrophoresis was performed at room temperature for 18 h at
6 W. Gels were autoradiographed on Kodak X-Omat™ AR
film (Kodak).
 
Sequencing Ig V(D)J-C Transcripts.
 
The Ig V
 
H
 
DJ
 
H
 
 cDNA
clones displaying an altered electrophoretic mobility in SSCP
gel as well as at least 5 clones from each patient with typical mo-
bility were analyzed by sequencing to confirm and characterize
the nature of the mutations (13, 32). Sequences were compared
with the germline counterpart (34) and with the original CLL
V
 
H
 
DJ
 
H
 
 sequence using MacVector v. 5.0 software (International
Biotechnologies).
 
Mutational Analysis.
 
The census of the somatic point-muta-
tions was determined by counting identical mutations in more
than one transcript only once. Comparison of the observed with
the expected frequency of replacement (R) and silent (S) point-
mutations was performed using the inherent mutation rate of the
CLL V
 
H
 
DJ
 
H
 
 sequences, calculated using the Inh. Sus. Calc. Pro-
gram, version 1.0 for the Macintosh as reported by B. Chang and
P. Casali (35). The expected frequency of mutations was calcu-
lated by taking into account the base composition of the unmu-
tated CLL V(D)J sequence, i.e., it was corrected by the frequency
of occurrence of the individual nucleotides, or di-, tri-, tetra-
nucleotides considered within the CLL B cells V(D)J sequence
assuming randomness. In the absence of negative or positive se-
lective pressure on a gene product, nucleotide changes yielding
amino acid R or S mutations are randomly distributed through-
out the coding sequences. If a DNA segment displays a number
of R mutations higher than that expected by chance alone, a pos-
itive selective pressure for variability is the likely cause. Con-
versely, if a DNA segment displays a number of R mutations
lower than that expected by chance, it is likely that a negative
pressure was exerted on the gene product to select against muta-
tions, such that the protein structure is preserved.
 
T Cells.
 
CD4
 
 
 
 T cells were positively selected from PBMCs
by fractionation through Histopaque 1077
 
®
 
 (Sigma-Aldrich) us-
ing CD4-conjugated magnetic beads
 
®
 
 (Miltenyi Biotec). Selected
cells were cultured in FCS-RPMI 1640, and expanded by
weekly stimulation with a feeder cell mixture containing irradi-
ated (1,200 rads) PBMCs, 100 
 
 
 
g/ml of phytohemagglutinin
(Life Technologies Inc.), and 100 U/ml of human recombinant
IL-2 (Genzyme). For T/B cell coculture experiments, CD4
 
 
 
 T
cells were used at least 2 wk after their last activation, and were
incubated for 6 h with 20 ng/ml of 13-phorbol 12-myristate ace-
tate (Sigma-Aldrich), and 500 ng/ml of ionomycin (Calbiochem-
Novabiochem) before culture with B cells.
 
B/T Cell Cocultures.
 
B/T cell cocultures were performed as
described previously (31). In brief, CLL B cells were cultured at
0.5 
 
 
 
 10
 
5
 
 cells per well in the presence of 2.5 
 
 
 
 10
 
5
 
 irradiated
(4,000 rads) CD4
 
 
 
 T cells, 10
 
6
 
 irradiated (4,000 rads) human
CD40L-transfected 293 cells (CD40L-293 cells) and cytokines,
including IL-4 (100 U/ml) and IL-2 (100 U/ml) in a U-bot- 
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tomed, 96-well plate (200 
 
 
 
l FCS-RPMI 1640 vol). To cross-
link the BCR, CLL B cells were incubated for 2 h at 4
 
 
 
C with
Sepharose
 
®
 
-conjugated rabbit Abs to human IgM and Ig (H 
 
 
 
 L)
chain (2 
 
 
 
g/ml; Irvine Scientific), and then washed with cold
PBS. After 7 d of culture, CLL B cells were collected, freed of
dead cells and debris by fractionation through Histopaque
 
®
 
 1077
(Sigma-Aldrich), exposed again to anti-BCR Abs, washed, and
reseeded over a new layer of irradiated T cells and CD40L-293
cells, in the presence of cytokines. At day 14 of culture, CLL cells
were harvested for total RNA extraction.
 
Results
 
CLL V
 
H
 
DJ
 
H
 
 Gene Diversification Determined by SSCP
Analyses.
 
The V
 
H
 
, D, and J
 
H
 
 genes expressed by the 18
CLL cases included in this study are listed in Table I. Of
the V
 
H
 
 genes identified, V
 
H
 
3 family members were the
most frequent, and J
 
H
 
4 was the most represented J
 
H
 
 gene,
as reported for other CLL cases (13). The origin of two D
gene segments could not be determined.
The Ig V
 
H
 
DJ
 
H
 
 cDNAs amplified by PCR using high-
fidelity 
 
Pfu
 
 Turbo
 
®
 
 DNA polymerase were cloned into ap-
propriate vectors for nested PCR amplification in the pres-
 
ence of [
 
 
 
-
 
32
 
P] dCTP. The amplified [
 
 
 
-
 
32
 
P] labeled
V
 
H
 
DJ
 
H
 
 cDNAs were then subjected to SSCP analysis. The
cDNAs from seven cases were homogeneous in electro-
phoretic mobility, as exemplified by case 216 (Fig. 1 A). In
the remaining 11 cases, the V
 
H
 
DJH cDNA transcripts dis-
played inconstant patterns of electrophoretic mobility, sug-
gesting a variable degree of intraclonal diversification, as
exemplified by case 105 (Fig. 1 B).
DNA Sequence Analyses Confirm that CLL B Cells Can
Accumulate New Ig V Gene Mutations and Thereby Intraclonally
Diversify. The sequences of the VHDJH cDNAs that dif-
fered in their SSCP mobility profiles from the majority of
the VHDJH cDNAs and the sequences of at least five cDNAs
representative of the dominant mobility profile were deter-
mined. In each case, all the VHDJH cDNAs were collinear,
strengthening the monoclonality of the leukemic cells.
However, as expected, intraclonal nucleotide differences
were detected in those VHDJH cDNAs that displayed altered
electrophoretic mobility (Table I). These findings were con-
sistent, regardless of how many transcripts were analyzed.
This suggests that the data provided by our SSCP analyses
accurately reflected the nature of the in vivo process.
Table I. Ig VHDJH Genes and Somatic Point-Mutations Expressed in CLL B Cells
GenBank
accession
number
Number of
transcripts
analyzed
Point mutations Number of
mutations
expected by
PCR error
CLL
case VH gene D gene JH gene Total Shareda
Partially
sharedb Uniquec
63 AF021974 1-46 D6-6 JH6b 29 0 0 0 0 0.29
67 AF021990 4-34 D2-15 JH4b 24 0 0 0 0 0.24
270 AY055487 1-02 D6-19   D3-9 JH4b 28 1 0 0 1 0.28
141 AF022005 4-34 D2-2 JH5b 29 2 0 0 2 0.29
156 AY055478 1-45 D2-2   D3-10 JH5b 27 2 0 0 2 0.27
7 AY055477 3-49 D3-3 JH5a 29 2 2 0 0 0.29
258 AY05485 1-69 D3-16 JH3b 30 3 0 0 3 0.30
216 AY055483 3-49 D5-12 JH6b 40 3 3 0 0 0.40
48 AF0211969 1-02 D6-13 JH3b 26 8 8 0 0 0.26
175 AY055484 3 (HHG4) D3-16 JH6b 28 9 2 0 7 0.28
249 AY055479 3-23 D2-21 JH4b 30 10 4 0 6 0.30
165 AY055482 3-15 D1-26 JH6b 30 14 14 0 0 0.30
178 AY055482 2-05 ND JH4b 30 17 13 0 4 0.30
136 AF022002 4-34 D2-2 JH6b 40 18 18 0 0 0.40
113 AF021989 2-05 ND JH4b 57 24 21 0 3 0.57
169 AY055480 3-33 D3-9 JH4b 50 26 24 0 2 0.50
261 AY055486 3-33 D5-12 JH4b 80 36 14 8 14 0.80
105 AF021986 3-23 D2-21 JH4b 60 40 5 11 24 0.60
Point-mutations in the Ig VHDJH gene transcripts of CLL B cells.
aShared, mutations shared by all the Ig VHDJH gene transcripts analyzed.
bPartially shared, mutations shared but some but not all the Ig VHDJH gene transcripts analyzed.
cUnique, mutations unique to distinct Ig VHDJH gene transcripts analyzed.
Based on error rate of 10 6 change/base/PCR cycle.632 Intraclonal Diversification in CLL B Cells
The nucleotide differences detected in these sequence
analyses were distributed randomly throughout VH. In
most instances, these differences were single base substitu-
tions, resulting in both S and R mutations. The frequency
of R mutations in the complementarity determining re-
gions (CDR) and framework regions (FR) of the VH gene
segments were not different from those expected by chance
alone, suggesting the lack of a selective pressure applied to
these Ig VH gene products.
Table I lists the number and characteristics of the cDNAs
analyzed in each CLL case. These transcripts are noted as
containing either “shared” (mutations present in all the
Ig VHDJH gene transcripts analyzed), “partially shared”
(mutations exhibited by some but not all VHDJH tran-
scripts), or “unique” point-mutations (mutations found
only in distinct VHDJH transcripts) as compared with the
respective germline template. The number of partially
shared and unique point-mutations differed between the
different cases analyzed, ranging from 1 (case 270) to 35
(case 105).
The Presence of Intraclonal Diversification Is Not Related to
the Initial Load of Shared Mutations. CLL cases can be di-
vided into two subgroups based on the presence of Ig V
gene mutations (13). To determine whether the degree of
leukemic B cell intraclonal diversification was related to
this original mutational load, we analyzed by linear regres-
sion the relationship of the number of partially shared and
unique mutations to the total number of mutations (Table
I). When all the cases were included in this analysis, the
degree of intraclonal diversification was found to be de-
pendent on the overall load of point-mutations (P  
0.05). However, when we excluded from the analysis the
two most intraclonally diversified cases (105 and 261) that
were atypical in their extent and patterns of diversification
(vide infra), the relationship was no longer significant (P
  0.1). Thus, intraclonal diversity appears to occur in
CLL B cells regardless of their original Ig V gene muta-
tional load.
The High Degree of Intraclonal Diversification in Certain
CLL Cases Allows the Construction of Genealogical Trees.
To outline the evolution of the changes that occurred
within each CLL clone, we aligned all the VHDJH cDNAs
to the closest germline gene sequence and analyzed them
on the assumption that the shared mutations occurred due
to single rather than independent events. This allowed us
to identify in each case the putative progenitor VHDJH
gene sequence and to assess the level of intraclonal com-
plexity. Of the 11 cases that exhibited intraclonal diversifi-
cation, nine (four originally unmutated CLL 141, 156, 258,
and 270, and five originally mutated CLL 113, 169, 175,
178, and 249) displayed only one level of diversification,
i.e., they expressed only unique mutations and no partially
shared mutations. However, two cases, CLL 105 and 261,
displayed different levels of complexity with several par-
tially shared mutations that allowed us to construct genea-
logical trees, as reported previously (36, 37).
CLL 261 showed 14 unique and eight partially shared
point-mutations, compared with the progenitor VHDJH
gene sequence (Fig. 2 A). These mutations identified a ge-
nealogical tree with three branches that spanned 1–3 gener-
ations. CLL 105 showed 24 unique point-mutations and 11
partially shared mutations, compared with the progenitor
VHDJH gene sequence (Fig. 2). There were five branches to
this genealogical tree, spanning 1–3 generations.
Induction of Somatic Mutation in CLL B Cells In Vitro.
To determine whether CLL B cells could be induced to
mutate the expressed VHDJH genes in vitro, the leukemic
cells from CLL cases 136 and 216 were reacted with im-
mobilized Abs to human Ig, and then cultured in the pres-
ence of activated normal allogeneic human CD4  T cells
and IL-2 and IL-4. After 14 d of culture, VHDJH-CH cDNAs
were analyzed as illustrated in Fig. 3. These cases were cho-
sen for these studies because their B cells did not exhibit
evidence for in vivo intraclonal variability (40 independent
bacterial clones containing VHDJH cDNAs screened by
SSCP and cDNA sequencing revealed that all cDNAs were
identical; Table I).
After in vitro stimulation, 3 of 32 (9%) VHDJH cDNAs in
CLL 136 and 5 of 34 (14.7%) in CLL 216 displayed a gel
mobility different from that of the corresponding cDNAs
from the unstimulated CLL cells (Fig. 4). All of the clones
with a different gel mobility pattern in SSCP contained
new point-mutations. In CLL 136, we detected three mu-
tations. These were independent point-mutations confined
to the VHDJH sequence (375 bp) and comprised three
transversions (clone 11: 4 G   C; clone 20: 23 G   T;
clone 9: 120 T   G). Thus, CLL 136 was induced to un-
dergo mutation with an overall frequency of 2.7   10 4
changes/base,  sixfold the PCR amplification error rate
with high-fidelity Pfu Turbo® DNA polymerase men-
tioned above. In CLL 216, a total of nine mutations were
Figure 1. SSCP analysis from two CLL cases displaying either the ab-
sence or presence of intraclonal diversification. All 27 VHDJH transcripts
from CLL 216 showed identical mobility (A). In CLL 105, seven of the
25 VHDJH transcripts showed a mobility pattern different from that dis-
played by the remaining 18 VHDJH transcripts (B). Sequence analysis
showed that the VHDJH cDNAs 1–3 were all collinear and collinear with
the most represented transcripts confirming their monoclonality. How-
ever, these transcripts displayed nucleotide variations distributed ran-
domly throughout the VH segment. VHDJH transcripts labeled 1 were
identical among themselves but different, though collinear, from the
VHDJH transcripts 2 and 3, and the most represented transcripts. VHDJH
transcripts 2 were all identical but different, though collinear, from the
VHDJH transcripts 1, 3, and the most represented transcripts. VHDJH tran-
scripts 3 were identical but different, though collinear, from the VHDJH
transcripts 1, 2 and the most represented transcripts.633 Gurrieri et al.
found in VHDJH transcripts. These were also independent
point-mutations that were confined to the VHDJH sequence
and consisted of nine transitions (clone 2: 25T   C, 36T   C,
88G   A; clone 4: 75T   C; clone 23: 87G   A, 21G   A;
clone 32: 21T   C, 157G   A; clone 18: 75A   G).
These mutations occurred at a frequency of 6.86   10 4
changes/base. Thus, these CLL cells were triggered to mu-
tate their expressed VHDJH genes with the same modalities
that induce mutations in normal B cells and monoclonal B
cell lines (30, 31).
Comparison of the Mutations Induced In Vitro with Those Oc-
curring In Vivo. Randomly occurring somatic point-muta-
tions are expected to be one-third transitions and two-
thirds transversions (38). Among the 128 original in vivo
shared VHDJH point-mutations, transitions exceeded trans-
versions, 72:56 (Table II). As in normal B cells, the original
shared mutations targeted A nucleotides at a frequency (46/
128 total mutations) that was  48% higher than expected
by chance alone, after correcting for base composition, i.e.,
normalizing for the relative occurrence of A in the unmu-
tated VHDJH sequence. A   G mutations accounted for
59% of the total A mutations and 38% of the total transi-
tions observed (Table II).
The 74 in vivo partially shared and unique point-muta-
tions showed a similar, albeit lesser bias for transitions over
transversions (39:35). However, these mutations lacked an
A base preference since only 15/74 mutations (20%) tar-
geted A nucleotides. Among the two cases with the more
extensive partially shared and unique mutations, CLL 261
demonstrated some evidence for A targeting (9/22 muta-
tions involving A), whereas CLL 105 exhibited minimal
evidence for this tendency (2/35 mutations involving A).
These two cases also differed in the ratio of transitions to
transversions detected among these mutations (CLL 261–
14:8 and CLL 105–15:20).
The in vitro–induced mutations also favored transitions
over transversions (9:3). However, the small number of
these mutations did not allow us to draw firm conclusions
regarding their nature.
Figure 2. Genealogical tree constructed using VHDJH sequences of CLL nos. 261 and 105. Point-mutations are indicated by their codon number and
the nature of the base change. Shared point-mutations and acquired unique point-mutations are indicated above and below the line, respectively. Vertical
bars depict S mutations, and lollipops depict R mutations. The putative intermediate elements are depicted with gray nuclei.
Figure 3. Schematic representation of the steps involved in the in vitro
induction of somatic hypermutation in CLL B cells.634 Intraclonal Diversification in CLL B Cells
Discussion
The generation of high affinity–specific antibodies
usually occurs in the germinal centers of organized lym-
phoid tissues and depends on a complex series of interac-
tions involving antigen activated B cells, specific T cells,
and follicular dendritic cells (39). This process usually in-
troduces point-mutations into Ig V genes and thus in-
creases receptor diversity (40, 41). Subsequently, certain
B cells are selected for survival and expansion based on
the affinity for antigen of the BCR encoded by the
newly mutated V genes (42, 43). Recently, it has been
suggested that somatic mutations may occur via another
pathway that does not require the participation of T cells
and may occur outside of classical germinal center struc-
tures (44, 45).
CLL B cells have been viewed as B lymphocytes that
cannot sustain effective somatic hypermutation of their Ig
VHDJH genes. However, analyses of the expressed Ig V
genes in CLL indicate that as many as 50% of IgM  CLL
and 75% of non-IgM  (IgG and IgA) CLL cases show evi-
dence of somatic mutations with a subset of these display-
ing R mutations in a pattern consistent with antigen selec-
tion (13). Thus, although the traditional views about the
presence of Ig V gene mutations in the leukemic cells of
this disease have been modified, the literature has remained
consistent in characterizing these V gene mutations as
static, without evidence for intraclonal instability and the
accumulation of diversity. Occasional studies have re-
ported the detection of somatic variants over time in typ-
Figure 4. In vitro induction of
somatic hypermutation. CLL 136
and CLL 216 did not exhibit evi-
dence of in vivo intraclonal diver-
sity (see Table I). After in vitro
stimulation, 3 of 32 VHDJH tran-
scripts in CLL 136 and 5 of 34 in
CLL 216 displayed gel mobilities
different from that of corresponding
transcripts obtained from the un-
stimulated CLL cells. Transcripts
were sequenced and each contained
at least one nucleotide change.
Table II. Nature of the Base Substitutions in the Ig VHDJH Gene Segment of CLL B Cells In Vivo and In Vitro
In vivo shared
point-mutations
In vivo partially shared and 
unique point-mutations
In vivo induced
point-mutations
Transitions G   A A   GC    TT    C Transitions G   AA    GC    TT    C Transitions G   AA    GC    T T   C
72 24 27 17 4 39 9 8 12 10 9
[12.8] [10.6] [9.8] [10.2] [7.4] [5.9] [5.4] [5.6]
Transversions G   C A   CC    AT    A Transversions G   CA    CC   A T    A Transversions G   CA    CC   A T   A
27 11 943 1 2 4233 1 1 0 00
[12.8] [10.6] [9.8] [10.2] [7.4] [5.9] [5.4] [5.6] [1.2] [0.92] [0.92] [0.92]
G   T A   TC    GT    GG    TA    TC    GT    GG    TA    TC    G T   G
29 5 10 5 9 23 7 5 7 4 2 1 0 01
[1.2] [0.92] [0.92] [0.92]
Total G   N A   NC    NT    N Total G   NA    NC    NT    N Total G   N A   N C   N T   N
128 40 46 26 16 74 20 15 22 17 12 6 1 0 5
[38.4] [31.8] [29.4] [30.7] [22.2] [17.7] [16.2] [17] [3.6] [2.76] [2.76] [2.76]
Shared, partially shared, and unique point-mutations in the Ig VHDJH gene segment of CLL B cells were analyzed in vivo and after in vitro induction.
Identical mutations in different transcripts of the same and different isotypes were assumed not to be independent and were counted only once.
The [expected] number of mutations (from a given nucleotide residue to another given nucleotide residue) was normalized for the base composition
of the unmutated VHDJH sequence. It was calculated by multiplying the frequency of occurrence of the nucleotide target of mutation in the unmutated
sequence by the total number of observed mutations, and dividing this product by three. For instance, the expected number of G   A mutations was
calculated by multiplying 0.30 (G frequency of occurrences the unmutated VHDJH sequence) by 128   38.4, divided by 3 (as G   A, G   C, and
G   T mutations have all the same theoretical probability to occur)   12.8.
Shared point-mutations in the Ig VHDJH gene segment of CLL 7, 216, 48, 175, 249, 165, 178, 136, 113, 169, and 105.
Partially shared and unique point-mutations in the Ig VHDJH gene segment of CLL 270, 141, 156, 175, 113, 169, 261, and 105.635 Gurrieri et al.
ical CLL cases and in a CD5  case (11, 46, 47). However,
these and other studies did not demonstrate detailed evi-
dence that significant intraclonal diversification occurred
in the leukemic cells of many CLL B cases, leading to the
conclusion that somatic mutation ceases as a consequence
of leukemic transformation (15–17). In this report, we
document that intraclonal VHDJH gene diversification and
clonal evolution do occur, albeit at variable degrees, in
 50% (11/18) of CLL B cases. Additionally, in those
cases in which this phenomenon is not detected in vivo,
diversity can be induced in vitro after providing physio-
logically relevant signals.
It is unlikely that these findings represent PCR errors.
First, the frequency of unique nucleotide changes ranged
from 3.5-fold (case 270) to 58-fold (case 105) higher than
the expected frequency of misinsertions calculated based on
the error rate of the high-fidelity Pfu Turbo® DNA poly-
merase provided by the manufacturer (10 6 base/cycle, i.e.,
0.01 base changes in a 375 bp DNA sequence after 30 cy-
cles). This published error rate is actually somewhat higher
than that calculated by us using the sequence data gener-
ated for the Ig CH region from the exact same cDNA used
for the VH data presented above and from other cDNA
prepared in an identical manner (0.6   10 6 base/cycle).
Nevertheless, we have used the manufacturer’s standard in
order to be conservative about our estimations. However,
even if we are extremely conservative in our calculations
and exclude those cases with  2 point-mutations, a signifi-
cant number of the remaining cases (7/18;  35%) still ex-
hibit from 3–21 mutations, which is inconsistent with these
PCR error rates. Second, when we subjected a subclone of
the Burkitt’s lymphoma cell line RAMOS (clone 1; refer-
ences 48 and 49) to the same RT-PCR-SSCP cloning and
sequencing procedure that we used for the CLL cases, a
mutation frequency of 1.3   10 4/bp was identified,
which compares favorably with the published mutation fre-
quencies determined for this RAMOS subclone (0.8–0.93  
10 4/bp; references 48 and 49). These two comparisons
also suggest that the reverse transcription step was not a
major source of error in our analyses, since these calcula-
tions of potential error are very similar despite the fact that
our analyses were based on RNA as the starting material
and the others on DNA.
Thus, the calculated rate of IgV gene mutations in these
B cells is clearly greater than that occurring spontaneously
in vivo elsewhere in the genome or to that attributable to
in vitro PCR error with high-fidelity Pfu Turbo® DNA
polymerase (Table I). It is also considerably lower than that
seen in other B cell lymphomas thought to originate in the
germinal center such as follicular lymphoma and Burkitt’s
lymphoma (50–54). These mutation frequency differences
are in line with the in vivo proliferative differences of the
malignant cells in CLL and these two subtypes of B cell
lymphoproliferative disorders.
Our findings indicate that a somatic mutation process is
active in at least certain members of the CLL clone, indi-
cating that the leukemic cells are not functionally inert, but
are in this regard functionally active. What is unclear is the
extent to which this mutational activity is mediated by the
classic IgV gene hypermutation mechanism, and also
whether it is induced by external stimuli or is inherent to
the B cells due to genetic alterations that occurred as a con-
sequence of the leukemic transformation. Although our
data do not directly indicate that the observed in vivo in-
traclonal diversification in CLL B cells is externally medi-
ated, there is evidence from these studies to suggest that
this could occur. In vitro stimulation through the BCR
and other critical costimulatory molecules expressed on ac-
tivated T cells induced mutations in those CLL B cells that
did not display intraclonal diversity in vivo (Fig. 4). These
mutations occurred at similar frequencies to those identi-
fied in vivo. We cannot formally exclude that mutated VH-
DJH transcripts predated the in vitro induction and were, in
some way, positively selected in our culture conditions.
However, the complete absence of mutating Ig VHDJH
transcripts among the large number of B cells analyzed be-
fore in vitro stimulation (Table 1) makes this possibility un-
likely. Thus, in these cases the BCR was still effective in
inducing somatic mutation in vitro implying that in vivo
external triggering could result in the observed Ig V gene
mutational heterogeneity and suggesting a potential role for
ongoing receptor stimulation in the evolution of the CLL
clone. The identification of mutations in only a small sub-
set of the CLL B cells might be consistent with this view,
since presumably not all members of the clone would have
access to the relevant antigen(s) or other BCR cross-link-
ers. Furthermore, the occurrence of intraclonal variation in
most, but not all, CLL B cells would be consistent with dif-
ferences in BCR-mediated signaling among CLL cases, as
has been suggested (13, 55–59). Alternatively, these point-
mutations could occur spontaneously or result from ongo-
ing stimulation via other receptors in leukemic subclones
made competent to receive them by genetic alterations.
The apparent lack of selection for R mutations in the CDR
and against R mutations in the framework regions among
the partially shared and unique new mutations may support
this interpretation.
In addition, the lack of targeting of R mutations to the
CDR and the apparent different nature of the originally
shared (A preference as in normal B cells) versus unique
point-mutations (non-A preference) favor the idea that the
unique point-mutations detected in the leukemic cells
might occur via mechanisms different from the canonical Ig
V gene hypermutation machinery. However, other features
(Tables I and II) are compatible with a canonical process of
somatic hypermutation (individual point-mutations result-
ing in more transitions than would be predicted for a sto-
chastic event; reference 38). Further studies will be neces-
sary to identify more precisely the mechanisms responsible
for this intraclonal V gene diversity. In this regard, we have
begun to study the relationship between the intraclonal
VHDJH gene diversification and the downregulation of
DNA pol  /pol   expression ratio. BCR engagement and
subsequent Ig V(D)J gene mutation can be associated with636 Intraclonal Diversification in CLL B Cells
downregulation of the translesion DNA pol  , and the
maintenance or upregulation of the translesion DNA pol  
(33), although studies in mice differ in this regard (60). In
preliminary studies, we have analyzed the expression of
DNA pol   and pol   in B cells of six CLL cases with and
four without intraclonal diversification. DNA pol   was
expressed at a normal level in all four cases without in vivo
intraclonal diversification, but was significantly downregu-
lated in all but one of the cases with intraclonal diversifica-
tion (unpublished data). DNA pol   was expressed at com-
parable levels in all cases, yielding normal and low pol  /
pol   expression ratios in the nondiversified and diversified
CLL cases, respectively. Furthermore, preliminary studies
suggest that activation-induced cytidine deaminase, that
appears to play an essential role in somatic hypermutation
(61, 62), can be detected by RT-PCR in some CLL cases,
although a correlation between enzyme mRNA expression
and intraclonal diversification is not clear at this point (un-
published data).
The CLL cases studied differed in the extent of intra-
clonal diversification identified. In most instances, the Ig V
gene mutations detected were unique to individual clonal
members within a specific CLL patient. However, in two
cases (nos. 105 and 261) mutations were shared among
clonal members (Table I), making it possible to construct
genealogical trees outlining the clonal evolution of the
CLL B cells (Fig. 2). The reason(s) for the occurrence of
such sublineages among certain, but not all, patients is not
clear. Several possibilities should be considered. First, if the
mutational machinery is not active at all points throughout
the “life” of the leukemic clone, then those cases in which
the machinery was active earlier and for a longer time in-
terval would be more likely to have shared mutations than
those cases in which the machinery was active later and for
a shorter time interval. In addition, differences in the inher-
ent proliferative rates of CLL cases or in individual mem-
bers of the clone could affect the number and frequency of
point mutations, and therefore the sharing of point-muta-
tions. Alternatively, additional genetic damage, induced by
this or other mutational processes, could have affected the
potential for somatic hypermutation, causing its accelera-
tion or termination in individual subclones. This latter issue
could be especially important not only for the diversifica-
tion of the Ig V gene repertoire, but also for the potential
level of “malignancy” of an individual subclone since in
normal B cells and in other B cell lymphoproliferative dis-
orders a somatic hypermutation process can target non-Ig
genes (32, 63–67). Finally, it is conceivable that the two
patients with the extensive mutational lineages (CLL nos.
261 and 105) differ from the others that exhibit unique mu-
tations but do not display this feature. For instance, the so-
matic mutation processes could have occurred by different
mechanisms and/or at different anatomic sites in these two
patients than those cases with solely unique point mutations
or even possibly with the original shared mutations. As
mentioned earlier, recent data suggest that human B cells
can accumulate Ig V gene mutations outside of classical ger-
minal center structures and adequate T cell help (44, 45, 68).
Consistent with its heterogeneity in terms of incidence
and magnitude, the occurrence of ongoing somatic hyper-
mutation in CLL B cells could also depend on the mi-
croenvironment. This dependency could lead either to an
induction or abolishment of the mutational process during
the course of the disease. It is becoming increasingly clear
that the natural history and behavior of CLL B cells reflect
not only intrinsic defects of the leukemic cells, but also ex-
trinsic factors. For instance, bidirectional lymphocyte–non-
lymphocyte cell interactions may lead to the inhibition of
apoptosis in neoplastic B cells (69–72). Similarly, the pres-
ence or absence of proliferation centers that resemble ger-
minal centers and alterations in the B/T cell network could
affect the ability of CLL B cells to undergo somatic hyper-
mutation (73, 74). Our finding that CLL B cells from cases
136 and 216, in which no intraclonal diversification was
found, effectively mutated the VHDJH genes in vitro upon
application of appropriate stimuli supports the notion that
external factors can overcome the putative “differentiation
block” of these leukemic cells. This is consistent with pre-
vious studies indicating that activated normal T cells or
polyclonal B cell activators can induce terminal differentia-
tion of CLL B cells (75, 76).
CLL cases can be segregated into two subgroups based
on the mutational load of the expressed VH sequence (13),
as defined by the number of shared mutations, and these
subgroups differ very significantly in clinical course and
outcome (26, 77). It is surprising that the occurrence and
frequency of intraclonal Ig V gene variants is independent
of the original mutation status of the individual CLL cases.
This suggests several points about the relatedness of these
two subgroups of CLL cases. First, these data indicate that
all CLL cells, regardless of their initial V gene mutation sta-
tus, retain the capacity to develop V gene mutations. If
these mutations occur via the normal Ig V gene hypermu-
tation process, then it is unlikely that the differences in V
gene mutations between the two subgroups is inherent and
a consequence of the leukemic process. Indeed, this might
support the notion that all CLL cases derived from antigen-
experienced (78) or memory (79) B cells. Second, these
data may provide some insight into whether the differences
in the load of shared mutations reflect distinct maturation
stages of mature B cells at which these CLL cells arose, e.g.,
pregerminal center B cells versus post-germinal center B
cells (10, 13, 14, 26, 77), or activation pathways that the
precursor B cells followed, e.g., T cell–dependent versus T
cell–independent triggers (13, 26). Finally, the occurrence
of significant intraclonal diversification in a subset of CLL
patients (nos. 261 and 105; Fig. 2) may occasionally impact
on the utility of IgV gene mutation status as a prognostic
marker in CLL. Recent studies indicate that the presence
of significant numbers of V gene mutations ( 2% VH dif-
ference from the most similar germline gene) correlates
with a relatively benign clinical course, whereas the ab-
sence of such mutations is associated with a more acceler-
ated and unfavorable clinical course and outcome (26, 77).
It remains to be seen whether the extent of V gene changes
that converted the VH gene mutation status of CLL 105637 Gurrieri et al.
from the “unmutated” to the “mutated” subgroup, will
impact on the predictive value of this marker in such cases,
although this seems unlikely since this type of “conversion”
appears to be relatively infrequent.
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